New two-year data show 39 percent of non-Hodgkin lymphoma patients treated with CAR T-cell therapy remain in remission

A new article shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta (axicabtagene ciloleucel) remained in remission more than two years (27.1 months median follow up) following therapy, and more than half of the patients treated remain alive.